Natural Alternatives International announced that its TriBsyn® ingredient will now be available for use in ready‑to‑drink beverages, protein drinks, dairy products, gummies and medical‑nutrition formulations, broadening the reach of its CarnoSyn® portfolio.
The company’s first‑quarter 2026 results showed a net loss of $0.3 million on sales of $37.7 million, a sharp improvement from the $2.0 million loss on $33.2 million in the same period a year earlier. The narrowing loss reflects stronger sales and better factory utilization, while the higher revenue signals growing demand for functional ingredients.
TriBsyn® is a clinically supported, paresthesia‑free beta‑alanine booster backed by more than 55 clinical studies and granted New Dietary Ingredient status. The expansion taps into the high‑growth wellness and medical‑nutrition markets that are driven by consumer interest in healthy aging, sustained energy and cognitive support.
Kenneth Wolf, President and Chief Operating Officer, said, “Consumers increasingly expect their wellness solutions to fit seamlessly into their daily routines. TriBsyn® empowers our partners to innovate across multiple high‑growth categories with a science‑backed ingredient that delivers meaningful benefits in formats consumers already enjoy.”
By entering beverages, dairy and medical‑nutrition segments, NAI aims to diversify its revenue base beyond contract manufacturing, positioning the company to capture growth in high‑margin wellness markets and move toward profitability in the second half of fiscal 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.